See more : Wells Fargo & Company PFD DIV EQUALIZ (WFCNP) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Adaro Energy Indonesia Tbk (ADOOY) Income Statement Analysis – Financial Results
- Community Financial Group, Inc. (Spokane, WA) (CFGW) Income Statement Analysis – Financial Results
- China Ting Group Holdings Limited (3398.HK) Income Statement Analysis – Financial Results
- NEXGEL, Inc. (NXGL) Income Statement Analysis – Financial Results
- NRP Stone Inc. (NRPI) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINC)
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
| Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.97M | 52.15M | 40.08M | 7.12M | 0.00 |
| General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
| SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
| Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
| Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
| Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
| EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
| Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
| Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
| Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Vincerx Pharma receives FDA clearance for early-stage leukemia trial
Vincerx Pharma shares moved higher after the biopharmaceutical company announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to commence a clinical trial of its investigational therapeutic VIP943 for patients with acute myeloid...
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx' first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx's development and regulatory expertise PALO ALTO, Calif., Aug. 22, 2023 (GLOBE...
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash balance expected to support planned operations into late 2024 PALO...
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in...
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will participate in a fireside...
Vincerx Pharma Announces $50 Million Private Placement
Strengthened financial position extends expected cash runway into 2023 Strengthened financial position extends expected cash runway into 2023
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors
4 Stocks With CEO Buys in the Past Month
According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial), Vincerx Pharma Inc. ( VINC...
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
First patient dosed by Vincerx marks significant milestone in Company's development First patient dosed by Vincerx marks significant milestone in Company's development
Source: https://incomestatements.info
Category: Stock Reports